Background: Alzheimer's disease and related disorders (ADRD) are prevalent in older adults, increase the costs of chronic heart failure (CHF) management, and may be associated with undertreatment of cardiovascular disease.
INTRODUCTION
Chronic heart failure (CHF) is a chronic disease of older adults, with incidence and prevalence that will continue to increase as the population ages. 1, 2 CHF is costly to diagnose and treat among Medicare beneficiaries, in part because it is the most common reason for hospitalization among older adults. [3] [4] [5] CHF is classified as an ambulatory care-sensitive condition, which means that with effective outpatient treatment and care, the disease can be managed without hospitalizations. 6, 7 Well-established evidence demonstrates the benefit of routine use of specific medications in the management of systolic heart failure. 8 In addition, patient adherence to these medications has been shown to reduce preventable hospitalizations and mortality. 8 As older adults with CHF typically have Ͼ1 chronic disease, 9, 10 understanding the effect of specific comorbid diseases on the benefit of CHF treatment will help clinicians optimize treatment plans for their patients. Alzheimer's disease and related disorders (ADRD) are highly prevalent in Medicare beneficiaries with CHF. The presence of ADRD has been associated with undertreatment of cardiovascular diseases, including CHF. [11] [12] [13] ЈADRD also increases the costs of CHF management. 14, 15 For example, Bynum et al 15 estimated that the average total costs in 2006 for treating a patient with CHF bot no ADRD was $17,739, whereas these costs increase to $21,315 to treat a patient with CHF and ADRD. Much of these costs are driven by greater numbers of hospitalizations and longer hospital stays in Medicare beneficiaries with CHF and ADRD; however, there is growing evidence that some of these hospitalizations may have been preventable with appropriate outpatient care, a frequent finding in ambulatory care-sensitive condition management. 6, 11 In the present study, we seek to describe the use of and adherence to CHF medications in patients with CHF with and without ADRD in order to guide management of CHF in patients with comorbid conditions such as ADRD. The objective of this study is to determine the relationship between comorbid ADRD and CHF medication use and adherence among Medicare beneficiaries with CHF and systolic dysfunction. This analysis is unique because it takes advantage of the recently available Medicare Part D prescription drug database and is, to our knowledge, one of the first studies to describe the impact of comorbid ADRD on CHF medication use and adherence in patients with CHF.
METHODS

Data Source and Study Sample
Using a 2-year (2006 -2007) cross-sectional design, we identified a cohort of Medicare beneficiaries with CHF from the Chronic Condition Data Warehouse (CCW) database. The CCW is provided by the Centers for Medicare and Medicaid Services and contains Medicare claims data for a 5% random sample of Medicare beneficiaries. The CCW has 21 predefined chronic condition cohorts, including CHF and ADRD, which are determined based on Medicare claims dating back to 1999.
The study sample was restricted to those with Medicare Parts A, B, and D hospital, health care, and prescription drug plan coverage during the entire study period (Part D coverage starting before July 1, 2006) in order to observe all medical claims and prescription events. We excluded individuals in Medicare Advantage plans because these individuals do not have Medicare Parts A and B claims. We also excluded those who died before January 1, 2007, in order to have at least the first year of observation on all individuals in which to capture medication use and adherence.
Beneficiaries with evidence of CHF were identified based on the CCW algorithm, defined as at least 1 inpatient, hospital outpatient, or carrier (physician) claim with a CHF diagnosis. 16 To confirm whether beneficiaries had active disease, we required beneficiaries to have at least 1 
MEASURES Dementia Status
Beneficiaries were classified as having ADRD using the CCW algorithm for ADRD, defined as at least 1 inpatient, skilled nursing facility, home health agency, hospital outpatient, or carrier (physician) claim with a dementia diagnosis (ICD-9-CM codes: 331.0, 331.1ϫ, 331.2, 331.7, 290.0, 290.1ϫ, 290.2ϫ, 290.3, 290.4ϫ, 294.0, 294.1ϫ, 294.8, 797). 16 The CCW definition is based on a study that found a sensitivity of 87% with this algorithm when compared with an Alzheimer's disease registry. 17 If beneficiaries met the CCW algorithm def-inition of ADRD anytime during their Medicare entitlement (back to 1999) through the end of 2006, we considered them as having ADRD.
CHF Medications and Adherence
CHF medications were selected based on the American College of Cardiology and the American Heart Association (ACC/AHA) treatment guidelines. 8 Medications included those indicated for chronic use in systolic CHF: angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), selected ␤-blockers (ie, carvedilol, bisoprolol, metoprolol succinate), aldosterone antagonists, and selected vasodilators (ie, combination hydralazine and isosorbide). ACE inhibitors or ARBs and ␤-blockers are recommended as first-line therapy, and aldosterone antagonists and vasodilators are recommended as additional therapies for selected patients. These evidence-based medications (EBMs) were selected because they have been shown to improve outcomes and/or reduce mortality in randomized clinical trials. 8,18 -32 We also separately examined any use of other drugs commonly used in heart failure that have not been shown to improve outcomes: diuretics, cardiac glycosides, and selected dihydropyridine calcium channel blockers (ie, amlodipine, felodipine). Although use of calcium channel blockers is not generally recommended in the ACC/AHA treatment guidelines, 8 the use of these medications has been demonstrated to be safe in patients with CHF and systolic dysfunction to treat comorbid hypertension or angina. 33 Consequently, we included these vasoselective calcium channel blockers in our study.
Two measures pertaining to CHF medications were estimated over the course of the 2-year study period: a binary indicator of EBM use and the medication possession ratio (MPR). The first measure, CHF medication use, is based on the presence of at least 1 prescription claim for a CHF medication in a given class and quantifies the prevalence of use. MPR is a measure of medi cation adherence and is calculated as the ratio of the sum of the days' supply from all claims for drugs in a given class to the duration of therapy for that class. The duration of therapy is defined as the number of days between the first and last claim in a drug class, plus the last claim's days' supply. EBM MPR was calculated as the ratio of the sum of the days' supply (numerator) to the sum of the durations (denominator) for each of the contributing drug classes. MPR was only assessed among those who received at least 1 prescription for a CHF EBM or for other CHF medications in a given class.
Other Covariates
Additional characteristics in the study included age (as of January 1, 2006), sex, race, and geographic region. General health indicators included evidence of specific comorbid conditions and the number of physician visits during the study period. Comorbidities for which a CCW indicator was available were identified using the CCW definition and were based on evidence in claims from 1999 through 2006; other conditions were identified by the presence of any claim in 2006 with a relevant ICD-9-CM diagnosis code. We also assessed the number of months each beneficiary resided in a longterm care (LTC) facility during the 2-year study period using an algorithm based on Healthcare Common Procedure Coding System codes modified from previous literature. 34, 35 Medicare coverage variables included original reason for entitlement, dual (Medicaid) eligibility status, and low income subsidy status.
Statistical Analyses
Univariate analyses were used to describe CHF cohort characteristics and medication use and adherence. Bivariate analyses examined the unadjusted relationship between dementia status and medication use and adherence. Multivariate models using generalized estimating equations were used to estimate the adjusted relationships between ADRD and medication use and adherence. EBM use and adherence were modeled as binary variables; for the latter, poor adherence was compared with fair to high adherence. We modeled adherence using 3 different thresholds to define poor adherence: MPR Ͻ0.50, MPR Ͻ0.80, and MPR Ͻ0.90. We used a Poisson distribution with a log link to allow estimation of prevalence ratios of drug use or adherence, rather than prevalence odds ratios. 36 Prevalence ratios (PRs) with 99% CIs are reported. All analyses were performed using SAS version 9.2 (SAS Institute Inc, Cary, North Carolina).
Because MPR was calculated among those who received any CHF EBM, the MPRs based on only 1 claim per medication class may be inflated. Therefore, we performed a sensitivity analysis restricting our sample to those for whom MPR was calculated based on Ͼ1 claim per medication class.
RESULTS
We identified 506,125 Medicare beneficiaries with a CHF diagnosis between 1999 and 2006 based on the CCW algorithm, of whom 9827 met the study inclusion criteria ( Figure) . The mean (SD) age of the cohort was 75.4 (11.6) years, and 60.7% were female ( Table I) .
More than 80% of beneficiaries in our sample were white, and 54% were receiving low income subsidy for their Part D benefit.
Among the CHF cohort, 2379 beneficiaries (24.2%) had evidence of an ADRD diagnosis in their Medicare claims. Those with an ADRD diagnosis were significantly older (80.8 vs. 73.6 years; P Ͻ 0.0001) and were more likely to be female (69.0% vs. 58.1%; P Ͻ 0.0001) compared with those with no evidence of ADRD. A higher proportion of those with ADRD had other conditions, including atrial fibrillation, chronic kidney disease, chronic obstructive pulmonary disease, hip fracture, osteoporosis, arthritis, stroke, anemia, and peripheral vascular disease. Certain conditions were less prevalent among those with ADRD compared with those without ADRD: hyperlipidemia, idiopathic cardiomyopathy, and valvular heart disease. On average, patients with ADRD had fewer outpatient physician visits during the study period compared with patients without ADRD. Residence in an LTC facility was more common among individuals with ADRD: just over one fourth of patients with CHF but no ADRD (26.2%) compared with almost two thirds of patients with CHF and ADRD (65.7%) spent Ն1 month in an LTC facility during the study period (P Ͻ 0.0001).
Overall, 96.3% of the cohort filled at least 1 CHF medication prescription during the study period (Table II). EBMs, diuretics, cardiac glycosides, and selected dihydropyridine calcium channel blockers were taken by 89.7%, 84.2%, 31.0%, and 23.1%, respectively. Compared with those without ADRD, a significantly lower proportion of beneficiaries with ADRD received an EBM (85.3% vs 91.2%; P Ͻ 0.0001). Use among those with ADRD was also lower for diuretics and cardiac glycosides compared with those without ADRD, although the differences were less pronounced for these classes. Use of selected dihydropyridine calcium channel blockers was higher among Regarding the 5 classes of EBMs, 77.1% of the cohort had at least 1 prescription for an ACE inhibitor or ARB and 56.7% had at least 1 prescription for a ␤-blocker during the study period. Aldosterone antagonists and vasodilators were used by 23.9% and 26.9% of the cohort, respectively. Use was significantly higher among those without ADRD compared with patients with ADRD for 4 of the 5 EBM classes: ACE inhibitors, ARBs, ␤-blockers, and aldosterone antagonists. Use of vasodilators was similar among those with and without ADRD.
Compared with beneficiaries without ADRD, those with ADRD had similar but a statistically significant higher mean MPR for EBM (0.86 vs 0.84; P ϭ 0.0001) and diuretics (0.81 vs 0.78; P Ͻ 0.0001). This trend of higher adherence among patients with ADRD versus without ADRD was seen in all therapeutic classes of EBMs but was only statistically significant for ␤-blockers (mean MPR, 0.86 vs 0.84; P ϭ 0.003). EBM adherence was higher among patients residing in LTC facilities in those with and without ADRD. Among patients with no evidence of an LTC facility stay during the study period, mean MPR was 0.84 in patients with and without ADRD, whereas mean MPR was higher among patients with Ն13 months of residence in an LTC facility (mean MPR of 0.89 among patients without ADRD and 0.87 among those with ADRD). This, in combination with the substantially higher proportion of individuals with ADRD who resided in LTC facilities, was the driving force behind the slightly but significantly higher MPRs found among beneficiaries with ADRD.
In the unadjusted model, beneficiaries with CHF and ADRD had lower CHF EBM use (PR ϭ 0.94; 99% CI, 0.91-0.95) compared with beneficiaries with CHF but no ADRD ( Table III ). The adjusted model showed an attenuated, although still significantly lower, relative prevalence of use for beneficiaries with ADRD (PR ϭ 0.97; 99% CI, 0.95-1.00; P ϭ 0.004). Adjusted PR estimates comparing use for patients with ADRD with those without ADRD ranged from 0.93 to 0.99 for the EBM subclasses, with vasodilators and aldosterone antagonists having the highest and lowest estimates, respectively.
Regarding adherence, both unadjusted and adjusted analyses demonstrated a nonsignificant effect of ADRD on poor adherence, defined as MPR Ͻ0.5 (unadjusted A sensitivity analysis for adherence models was performed among those whose MPR was calculated based on Ͼ1 claim per medication class (n ϭ 8589). These results did not differ from the original results, providing unadjusted and adjusted estimates of the effect of ADRD on poor adherence of 0.83 (99% CI, 0.59 -1.15) and 1.13 (99% CI, 0.78 -1.64), respectively.
DISCUSSION
Using newly available Medicare Part D data, we determined the effect of comorbid dementia on CHF treatment patterns and adherence among a cohort of Medicare beneficiaries. A recent study that analyzed the impact of Part D on medication use and adherence found improved access and adherence to ACE inhibi- ACE ϭ angiotensin-converting enzyme; ARB ϭ angiotensin receptor blocker; CHF ϭ chronic heart failure; EBM ϭ evidence-based guideline CHF medication; MPR ϭ medication possession ratio. *ADRD vs no ADRD (t test for comparison of means, 2 for comparison of proportions). † MPR is calculated among those who used the relevant CHF medication class.
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The American Journal of Geriatric Pharmacotherapy tors, ARBs, and â-blockers for treatment of CHF following the implementation of Part D. 37 Our study adds to this by examining CHF medication use and adherence in a nationally representative sample and describing differences between those with and without ADRD. Despite the overall improvements in access observed by Donohue et al, 37 our findings demonstrate that beneficiaries with CHF and ADRD were less likely to receive any of the classes of EBMs with the exception of vasodilators and were more likely to receive selected dihydropyridine calcium channel blockers. Overall, this finding is consistent with previous reports of lower use of cardiac medications in patients with ADRD and cardiovascular diseases. 12,38 -40 Although overall adherence was high among those who received EBM, beneficiaries with ADRD and CHF had slightly higher adherence than beneficiaries with CHF and no ADRD. The higher adherence among patients with ADRD was consistent across all EBM subclasses, although only significant for ␤-blockers, as well as for diuretics. However, adjusting for confounding factors, including nursing home residence, removed the association between ADRD status and adherence. The higher adherence observed among those with ADRD was likely due to careful administration of medications in LTC settings and assisted living facilities, because we found adherence rates were higher among those residing in nursing homes, and beneficiaries with CHF and ADRD were more likely to reside in nursing homes.
The recent passage of the National Alzheimer's Project Act (NAPA) 41 highlights the importance of our findings. Management of chronic diseases such as CHF in patients with dementia is associated with higher rates of hospitalization and costs compared with those who do not have dementia. 11, 14, 42 Thus, interventions targeting treatment with EBMs for CHF, even among patients with ADRD, may help to reduce CHF-related hospitalizations, particularly since we found adherence to medications in this population to be high.
Our findings should be interpreted with the following study limitations in mind. The cross-sectional study design limits our ability to make causal inferences. Although we did not include individuals with a first diagnosis of ADRD in 2007, CHF medication use may have preceded a dementia diagnosis that occurred late in 2006. However, because dementia is a progressive disease, it is likely that symptoms were present before an official diagnosis and therefore still may have influenced decisions regarding CHF medications. Because this analysis was based on administrative data, measurement and disease ascertainment were limited by information available in such data. We attempted to address this limitation by restricting the study sample to those with a diagnosis of CHF and who had systolic dysfunction (ICD-9-CM codes: 428.2x, 428.4x). This method of identification has a specificity of 97.1% against ejection fractions recorded in the medical record, but it has a low sensitivity (11.8%). 43 We chose this definition to avoid capturing patients with rule-out diagnoses who would be included when using broad group CHF diagnosis codes and therefore include only those in whom treatment would be truly indicated; however, the low sensitivity and the fact that a majority of CHF diagnoses in administrative claims are for "unspecified" disease suggests that using ICD-9 codes to identify individuals with systolic dysfunction results in many false-negatives. Also, the lower use of ␤-blockers may have been influenced by restricting ␤-blocker EBMs to only the 3 ␤ blockers recommended in the guidelines for patients with systolic dysfunction, 8 so patients in our cohort identified as nonusers may have been using non-evidence-based ␤-blockers. An observational study by Kramer et al 44 suggested that non-EBM ␤-blockers are as effective as evidence-based ␤-blockers in a cohort not limited to those with systolic failure. However, our study was restricted to those with systolic dysfunction; therefore, we chose to include only medications that had demonstrated efficacy in randomized controlled trials for systolic CHF and were indicated in the CHF treatment guidelines. In addition, we note that there is only 1 randomized controlled trial restricted to treatment of older patients with CHF (mean age, 76 years) with nebivolol, 45 and the lack of trials focused on use of these drugs in older adults may also have contributed to the low use seen in our cohort.
Another limitation was the lack of ability to determine specific reasons for nonuse of or poor adherence to EBM (eg, patient refusal, history of adverse effects, patient health literacy). Moreover, we observed higher MPR levels for CHF beneficiaries with ADRD, which may be due to residence in LTC facilities or caregiver behavior in those residing in the community. Although we did not have information about caregiver status, we controlled for the higher proportion of those with ADRD in LTC facilities, where a caregiver administers medications. In addition, we chose to use MPR over a measure of proportion of days covered because we were interested in exploring the consistency of medication use for those using medications during their period of drug exposure. It should be noted that MPR may overestimate adherence when a beneficiary switches medications or has therapeutic duplication, 46 so adherence results based on MPR may provide upper estimates. However, we calculated the numerator of MPR using days' supply at a drug level and then "rolled up" MPR to the class level. This reflects the weighted average of the proportion of days that any drug in a given class is available instead of simply adding the days' supply for all drugs in a given class, thus removing the potential for overestimation due to the numerator. Additionally, adherence was determined by refill patterns, and we did not have information on actual ingestion of the medication. However, adherence as ascertained by prescription refill patterns has been shown to be a valid measure of patient adherence. [47] [48] [49] Although our study sample was drawn from a random sample of Medicare beneficiaries with CHF who had systolic dysfunction, our findings may not be generalizable to all Medicare patients with CHF due to study exclusion criteria. Specifically, these results cannot be assumed to represent treatment of types of CHF other than systolic dysfunction. In addition, patients included in the analysis were more likely to be younger, of minority race, reside in the South or West, and to have Medicare entitlement due to disability and/or end-stage renal disease compared with those who were excluded (data not shown).
Finally, the large sample size in this study allowed us to calculate precise estimates of the relationship between comorbid ADRD and CHF medication use and adherence among beneficiaries with CHF; however, it remains to be studied if the statistically significant results translate into clinically significant differences that need to be addressed.
CONCLUSIONS
This analysis of CHF medication use and adherence among Medicare beneficiaries documents that patients with CHF and comorbid ADRD are less likely to receive EBM than patients with CHF without comorbid ADRD. However, overall adherence was high among those who did receive CHF EBM, and individuals with ADRD had slightly higher adherence to these medications than those with no ADRD, perhaps due to assistance taking medications that patients with ADRD receive from LTC facilities or caregivers. Patients with ADRD had lower EBM use in general, and we found low use of specific EBMs such as ␤-blockers in both groups. Therefore, interventions targeting increased treatment with specific EBMs for CHF, even among patients with ADRD, may be of benefit and help to reduce CHF-related hospitalizations.
With the recent passage of NAPA, a national plan will emerge for the management of ADRD; the optimization and increase in the use of EBM in this population for managing comorbid conditions such as CHF is unknown. Future studies, using longitudinal designs and longer follow-up periods as additional years of data become available, are warranted to examine this phenomenon more fully across the management of other chronic diseases in patients with ADRD to help inform chronic disease management in the ADRD population. In particular, future work should determine the effect of evidence-based CHF treatment on patients with comorbid ADRD on individual patient and societal outcomes such as risk of hospitalization and associated costs of hospitalization. 
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